GlobeNewswire·Oct 26, 2026, 9:00 AM ET

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

The global cancer immunotherapy market is projected to grow from $166.4 billion in 2026 to approximately $305.8 billion by 2033 according to Grand View Research.
Key immuno-oncology developments include personalized cancer vaccines, bispecific antibodies, new lung cancer therapies, & CAR-T cell treatments for solid tumors.
GT Biopharma (NASDAQ: GTBP) will present data on inhibiting KRAS to sensitize pancreatic cancer to NK cell immunotherapy at the SITC 2026 Annual Meeting.
Moderna (NASDAQ: MRNA) & Merck announced positive Phase 3 results for intismeran combined with KEYTRUDA, showing a 42% reduction in recurrence risk for melanoma patients.
Iovance Biotherapeutics (NASDAQ: IOVA) reported a 62.5% objective response rate for lifileucel combined with pembrolizumab in frontline advanced melanoma.
Genmab (NASDAQ: GMAB) presented updated Phase 2 data for petosemtamab in metastatic colorectal cancer, showing 75% response rates in first-line settings.
Pfizer (NYSE: PFE) shared Phase 2 results for its 25-valent pneumococcal vaccine candidate, demonstrating robust immune responses in infants.
The article lists GT Biopharma, Moderna, Iovance Biotherapeutics, Genmab, & Pfizer as companies driving growth in the immuno-oncology sector.
Market figures are third-party estimates, & investing in biotechnology carries significant risks including clinical trial failure & regulatory delays.